FierceBiotechOriginal article
{"a":[{"_":"Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail","$":{"href":"/biotech/bausch-lomb-gives-next-breakthrough-glaucoma-eye-drops-after-phase-2-fail","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Bausch + Lomb has discontinued development of a glaucoma eye drop candidate following a failed phase 2 study, abandoning the treatment as a potential next-generation option for the indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 study failed for glaucoma eye drops
Importance:6/10
Sentiment:
-0.90
glaucomaeye dropsphase 2 failurediscontinued
Related Companies
Read the original article
Published by FierceBiotech on July 10, 2026 5:14 AM